Patents Review in siRNA Delivery for Pulmonary Disorders
Nirav I. Khatri, Mohan N. Rathi, Atul A. Kolte, Girish G. Kore, Manisha S. Lalan, Sonia Trehan and Ambikanandan R. Misra
Affiliation: Professor in Pharmacy and Dean, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Post Box No.: 51, Kalabhavan, Vadodara - 390 001,Gujarat state, India.
siRNA inhibits protein expression by degrading complementary mRNA sequence and hence, it is widely applicable for the treatment of various diseases where single or multiple gene knock down is necessary. Due to the severity and lethality of pulmonary diseases, siRNA has been focused for improved health in these diseases. Pulmonary accumulation of siRNA can be achieved by different means like intranasal or inhalation administration or intratracheal route which is mainly utilized for in vivo animal studies. However, various pulmonary obstacles and intracellular barriers for siRNA transport challenge this novel therapeutic moiety. Researchers have utilized different viral and non-viral delivery vectors for intracellular delivery of siRNA to knock down target mRNA. The promise of RNA interference, mediated by siRNAs, has revolutionized the prospects for modulating gene expression as a way to achieve therapeutic aims in disease treatment. This review focuses on patents describing the siRNA delivery either in naked form or along with a single/multiple delivery vectors. Many inventors have shown promising results for pulmonary utilization of siRNA and more concentration on delivery system may make this genomic approach available to the clinics soon.
Keywords: Aerosol, dry powder inhaler, genomics, intranasal, lung, nebulizer, pulmonary delivery, siRNA, INTRATRACHEAL ROUTE, RESPIRATORY SYNCYTIAL VIRUS
Rights & PermissionsPrintExport